358 related articles for article (PubMed ID: 23658373)
1. Incidence and risk of treatment-related mortality in cancer patients treated with the mammalian target of rapamycin inhibitors.
Choueiri TK; Je Y; Sonpavde G; Richards CJ; Galsky MD; Nguyen PL; Schutz F; Heng DY; Kaymakcalan MD
Ann Oncol; 2013 Aug; 24(8):2092-7. PubMed ID: 23658373
[TBL] [Abstract][Full Text] [Related]
2. Incidence and risk of treatment-related mortality with mTOR inhibitors everolimus and temsirolimus in cancer patients: a meta-analysis.
Qi WX; Huang YJ; Yao Y; Shen Z; Min DL
PLoS One; 2013; 8(6):e65166. PubMed ID: 23785409
[TBL] [Abstract][Full Text] [Related]
3. Hematologic toxicities associated with mTOR inhibitors temsirolimus and everolimus in cancer patients: a systematic review and meta-analysis.
Xu J; Tian D
Curr Med Res Opin; 2014 Jan; 30(1):67-74. PubMed ID: 24028709
[TBL] [Abstract][Full Text] [Related]
4. Risk of infections in renal cell carcinoma (RCC) and non-RCC patients treated with mammalian target of rapamycin inhibitors.
Kaymakcalan MD; Je Y; Sonpavde G; Galsky M; Nguyen PL; Heng DY; Richards CJ; Choueiri TK
Br J Cancer; 2013 Jun; 108(12):2478-84. PubMed ID: 23736025
[TBL] [Abstract][Full Text] [Related]
5. First-line Mammalian target of rapamycin inhibition in metastatic renal cell carcinoma: an analysis of practice patterns from the International Metastatic Renal Cell Carcinoma Database Consortium.
Harshman LC; Kroeger N; Rha SY; Donskov F; Wood L; Tantravahi SK; Vaishampayan U; Rini BI; Knox J; North S; Ernst S; Yuasa T; Srinivas S; Pal S; Heng DY; Choueiri TK
Clin Genitourin Cancer; 2014 Oct; 12(5):335-40. PubMed ID: 24787966
[TBL] [Abstract][Full Text] [Related]
6. Treatment outcome with mTOR inhibitors for metastatic renal cell carcinoma with nonclear and sarcomatoid histologies.
Voss MH; Bastos DA; Karlo CA; Ajeti A; Hakimi AA; Feldman DR; Hsieh JJ; Molina AM; Patil S; Motzer RJ
Ann Oncol; 2014 Mar; 25(3):663-668. PubMed ID: 24458473
[TBL] [Abstract][Full Text] [Related]
7. mTOR inhibitors in advanced renal cell carcinoma.
Voss MH; Molina AM; Motzer RJ
Hematol Oncol Clin North Am; 2011 Aug; 25(4):835-52. PubMed ID: 21763970
[TBL] [Abstract][Full Text] [Related]
8. Incidence and risk of rash to mTOR inhibitors in cancer patients--a meta-analysis of randomized controlled trials.
Shameem R; Lacouture M; Wu S
Acta Oncol; 2015 Jan; 54(1):124-32. PubMed ID: 24914484
[TBL] [Abstract][Full Text] [Related]
9. Differences in adverse event profiles between everolimus and temsirolimus and the risk factors for non-infectious pneumonitis in advanced renal cell carcinoma.
Nozawa M; Ohzeki T; Tamada S; Hongo F; Anai S; Fujimoto K; Miki T; Nakatani T; Fukasawa S; Uemura H
Int J Clin Oncol; 2015 Aug; 20(4):790-5. PubMed ID: 25342378
[TBL] [Abstract][Full Text] [Related]
10. Treatment-related fatigue with everolimus and temsirolimus in patients with cancer-a meta-analysis of clinical trials.
Peng L; Zhou Y; Ye X; Zhao Q
Tumour Biol; 2015 Feb; 36(2):643-54. PubMed ID: 25281033
[TBL] [Abstract][Full Text] [Related]
11. Attributable Risk of Infection to mTOR Inhibitors Everolimus and Temsirolimus in the Treatment of Cancer.
Garcia CA; Wu S
Cancer Invest; 2016 Nov; 34(10):521-530. PubMed ID: 27791402
[TBL] [Abstract][Full Text] [Related]
12. Everolimus in renal cell carcinoma.
Wang Y
Drugs Today (Barc); 2010 Aug; 46(8):557-66. PubMed ID: 20830316
[TBL] [Abstract][Full Text] [Related]
13. Incidence and risk of high-grade stomatitis with mTOR inhibitors in cancer patients.
Shameem R; Lacouture M; Wu S
Cancer Invest; 2015 Mar; 33(3):70-7. PubMed ID: 25635371
[TBL] [Abstract][Full Text] [Related]
14. Everolimus vs. temsirolimus for advanced renal cell carcinoma: use and use of resources in the US Oncology Network.
Vogelzang NJ; Bhor M; Liu Z; Dhanda R; Hutson TE
Clin Genitourin Cancer; 2013 Jun; 11(2):115-20. PubMed ID: 23063578
[TBL] [Abstract][Full Text] [Related]
15. A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer.
Powles T; Wheater M; Din O; Geldart T; Boleti E; Stockdale A; Sundar S; Robinson A; Ahmed I; Wimalasingham A; Burke W; Sarker SJ; Hussain S; Ralph C
Eur Urol; 2016 Mar; 69(3):450-6. PubMed ID: 26364551
[TBL] [Abstract][Full Text] [Related]
16. First-Line and Sequential Use of Pazopanib Followed by Mammalian Target of Rapamycin Inhibitor Therapy Among Patients With Advanced Renal Cell Carcinoma in a US Community Oncology Setting.
Vogelzang NJ; Hackshaw MD; Hutson TE; Bhowmik D; Yap M; Rembert D; Jonasch E
Clin Genitourin Cancer; 2015 Jun; 13(3):210-7. PubMed ID: 25498215
[TBL] [Abstract][Full Text] [Related]
17. Everolimus for the treatment of advanced renal cell carcinoma.
Amato R
Expert Opin Pharmacother; 2011 May; 12(7):1143-55. PubMed ID: 21470068
[TBL] [Abstract][Full Text] [Related]
18. Rechallenge with mTOR inhibitors in metastatic renal cell carcinoma patients who progressed on previous mTOR inhibitor therapy.
Maj-Hes A; Medioni J; Scotte F; Schmidinger M; Kramer G; Combe P; Gornadha Y; Elaidi R; Oudard S
Oncology; 2013; 85(1):8-13. PubMed ID: 23797151
[TBL] [Abstract][Full Text] [Related]
19. Everolimus and temsirolimus are not the same second-line in metastatic renal cell carcinoma. A systematic review and meta-analysis of literature data.
Iacovelli R; Santoni M; Verzoni E; Grassi P; Testa I; de Braud F; Cascinu S; Procopio G
Clin Genitourin Cancer; 2015 Apr; 13(2):137-41. PubMed ID: 25160521
[TBL] [Abstract][Full Text] [Related]
20. Biological toxicities as surrogate markers of efficacy in patients treated with mTOR inhibitors for metastatic renal cell carcinoma.
Jebali M; Elaidi R; Brizard M; Fouque J; Takouchop C; Sabatier B; Oudard S; Medioni J
BMC Cancer; 2017 Jan; 17(1):27. PubMed ID: 28061764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]